retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% ESC 2024: Retatrutide improves lipid

Only 8% of participants experienced minimal response (under 5% loss)

That single target does a remarkable amount of work

Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes

These are real advancements that will make effective GLP-1 treatment accessible to more people without the need for dubious supplements

Why is the weight loss journey difficult